AC Immune (ACIU) Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

Does the media favor SNDX or ACIU?

In the previous week, Syndax Pharmaceuticals had 10 more articles in the media than AC Immune. MarketBeat recorded 13 mentions for Syndax Pharmaceuticals and 3 mentions for AC Immune. AC Immune's average media sentiment score of 1.82 beat Syndax Pharmaceuticals' score of 0.20 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders & institutionals have more ownership in SNDX or ACIU?

51.4% of AC Immune shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, SNDX or ACIU?

Syndax Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Is SNDX or ACIU more profitable?

AC Immune's return on equity of -28.26% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%
AC Immune	N/A	-28.26%	-18.98%

Which has higher earnings & valuation, SNDX or ACIU?

AC Immune has higher revenue and earnings than Syndax Pharmaceuticals. AC Immune is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$16M	68.29	-$209.36M	-$3.63	-3.53
AC Immune	$40.97M	6.30	-$60.41M	-$0.46	-5.67

Do analysts recommend SNDX or ACIU?

Syndax Pharmaceuticals currently has a consensus price target of $36.20, suggesting a potential upside of 182.81%. AC Immune has a consensus price target of $12.00, suggesting a potential upside of 359.77%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
AC Immune	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor SNDX or ACIU?

Syndax Pharmaceuticals received 129 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 65.37% of users gave Syndax Pharmaceuticals an outperform vote while only 62.47% of users gave AC Immune an outperform vote.

Company	Underperform	Outperform
Syndax Pharmaceuticals	Outperform Votes 387 65.37%	Underperform Votes 205 34.63%
AC Immune	Outperform Votes 258 62.47%	Underperform Votes 155 37.53%

Summary

AC Immune beats Syndax Pharmaceuticals on 11 of the 17 factors compared between the two stocks.